Quote | XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (NASDAQ:XOMAO)
Last: | $25.10 |
---|---|
Change Percent: | 0.08% |
Open: | $25.1 |
Close: | $25.10 |
High: | $25.1 |
Low: | $25.1 |
Volume: | 521 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
News | XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (NASDAQ:XOMAO)
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in...
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene ...
Message Board Posts | XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (NASDAQ:XOMAO)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock Company Name:
XOMAO Stock Symbol:
NASDAQ Market:
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in...
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene ...
2024-04-25 18:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...